US regulatory status: approved.
pharma · Chronic obstructive pulmonary disease (COPD) · Partial Epilepsy in Children and Adolescents
Bial Portela &
Bial Portela & Companhia S.A.
Bial Portela & drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
EU HQ
EMA registrant Type
Company details
- Status
- Public
- HQ
- EU
- Programs
- 7
- Drugs
- 7
- Patents
- 3
Bial Portela & pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Bial Portela & drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Vasopressin receptor.
- Target
- Vasopressin receptor
- Mechanism
- Vasopressin receptor agonist
-
eslicarbazepine acetate
Nervous system (N03)US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
Development asset linked to Bial Portela & in public FDA and regional records.
-
metformin hydrochloride
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Mitochondrial complex I (NADH dehydrogenase).
- Target
- Mitochondrial complex I (NADH dehydrogenase)
- Mechanism
- Mitochondrial complex I (NADH dehydrogenase) inhibitor
-
Development asset linked to Bial Portela & in public FDA and regional records.
-
Development asset linked to Bial Portela & in public FDA and regional records.